258results about "General/multifunctional contrast agents" patented technology

The invention discloses a medical developing marker and a manufacturing method thereof, and relates to the field of medical instruments, the medical developing marker comprises a closed tube, the outer wall of the closed tube is provided with a bionic barb structure, the bionic barb structure is distributed in a flexible zigzag convex manner, and the bionic barb structure and the closed tube are integrally formed through an injection molding process; a closed cavity is arranged in the closed tube, four developing strips are symmetrically arranged in the tube wall of the closed cavity, the tube wall of the region where the developing strips are located is etched to form a weak band, and a developing material layer and a sustained-release medicine layer are sequentially deposited at the weak band. The developing material layer and the sustained-release drug and / or marked nano-particle layer are alternately deposited to form a functional composite layer, and the functional composite layer can directionally rupture to release the therapeutic drug under the action of implantation pressure. The marker integrates the functions of precise development, tissue anchoring and drug sustained release, is adaptive to multi-mode imaging such as ultrasonic imaging, X-ray imaging, CT imaging, MRI imaging and PET-CT imaging, and has remarkable clinical value in precise positioning treatment of solid tumors such as breast cancer and liver cancer.

The invention discloses a radionuclide-labeled collagen hybrid peptide probe as well as a preparation method and application thereof. The chemical structural general formula of the radionuclide-labeled collagen hybrid peptide probe is (metal nuclide-chelating agent)-Linker-CHP, wherein the metal nuclide is selected from any one of Al18F, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 89Zr, 111In, 177Lu, 186Re and 225Ac, and the metal nuclide is selected from any one of Al18F, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 89Zr, 111In, the chelating agent is selected from any one of NODAGA, NOTA2 and DOTA; linker is a connecting joint, and CHP is a collagen hybrid peptide with a polypeptide sequence of (GfO) n or (GPO) n. The probe not only has the characteristic of radiochemical marking stability, but also has the excellent biological distribution characteristics of high uptake in target organs such as tumors and low uptake in non-target organs such as liver and kidney, and has a good clinical application prospect.

Keto-amide based FAP-targeted ligands, conjugate comprising same, pharmaceutical compositions comprising same, and methods of use for imaging and treatment.

The tumor stroma, which accounts for a large portion of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here, we focus specifically on a subpopulation of stromal cells known as cancer-associated fibroblasts, which are present in over 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAPs, which are undetectable in adult normal tissues but are associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.

This disclosure relates to polyethylene glycol (PEG)-functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The invention belongs to the technical field of biochemistry, and relates to a fluorescence / photoacoustic bimodal probe responding to Cu (I) and a preparation method and application thereof. The fluorescence / photoacoustic bimodal probe responding to Cu (I) has high selectivity and sensitivity, has efficient tumor targeting ability, can be used for dynamic tracing of Cu (I) in tumor, can dynamically image Cu (I) in tumor by combining with a three-dimensional photoacoustic / living body fluorescence imaging technology and the probe HCyCu1, provides a new detection means for detection of Cu (I), and has wide application prospects. And a potential tool is provided for tumor diagnosis. According to the preparation method of the bimodal probe, the adopted raw materials are easy to obtain, the reaction conditions are mild and easy to control, the reaction cost is saved, and the yield of a target product is guaranteed. The structural formula of the probe is as follows: # imgabs0 #.

This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The present invention provides a glutathione-activated co-assembled nanoprobe and a preparation method and application thereof, belonging to the technical fields of chemical synthesis, biological analysis and detection, tumor imaging and treatment. In the present invention, amphiphilic small molecule probes 1-Zn-PPA and 1-NLG are constructed, and the probes 1-Zn-PPA and 1-NLG can be co-assembled in a solution to form co-assembled nanoprobes 1-NPs. The nanoprobes 1-NPs can accumulate at the tumor site under the tumor EPR effect and the targeting action of cRGD on the probe surface, and disassemble under the action of GSH present in the tumor reducing environment to release Gd-containing hydrophilic small molecule 2-Gd, light / sound-sensitive drug Zn-PPA-SH and immune adjuvant drug NLG919. The nanoprobes 1-NPs can realize combined sonodynamic therapy / photodynamic therapy / immunotherapy of living tumors. The nanoprobes 1-NPs have good applications in fluorescence imaging, magnetic resonance imaging, and the preparation of tumor treatment drugs and tumor-killing devices.

The present invention relates to a particulate structure comprising: a / biodegradable polymer particles; b / gold nanoparticles whose surfaces are coated with a macrocyclic chelating agent that complexes at least one target ion and / or radionuclide for medical imaging; and c / a polycation that has a positive charge over a pH range of 5 to 11, wherein the gold nanoparticles b / are encapsulated in the polymer particles a / and / or adsorbed to the surface of the polymer particles a / . The present invention also relates to a method for producing the particulate structure. The present invention further relates to the use of the particulate structure for radiotherapy or chemotherapy in cancer treatment.

To provide novel therapeutic methods for prostate cancer.SOLUTION: Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.SELECTED DRAWING: Figure 2

The application discloses a kind of polypeptide modified long afterglow nano-complex and its preparation method and application, nano-complex, for core-shell structure, core-shell structure is composed of the core body in inside and the shell that surrounds core body, core body is long afterglow nanomaterial, shell is by polypeptide modification and modified molecule modification, and drug loaded dendritic polymer;The nano-complex of the application can realize multiscale imaging to osteoclast, through in vivo afterglow imaging and in vivo two-photon microscopic imaging, the morphology, migration and distribution of osteoclast can be more accurately analyzed, avoid photo toxicity and background interference, improve imaging sensitivity;The nano-complex of the application is loaded with osteoporosis treatment drug alendronate ALN, and treatment drug can be replaced according to actual demand, and treatment scheme is adjusted, so that the drug loading system has universality.

Disclosed herein is an antibody-conjugate comprising a monoclonal antibody that specifically binds to GD2 and comprises a heavy chain and a light chain comprising heavy and light chain variable regions set forth as SEQ ID NOs: 3 and 4, respectively. The monoclonal antibody can be conjugated to a near-infrared fluorescent dye and diethylenetriaminepentaacetic acid (DTPA). In several aspects, the antibody-conjugate further comprising Indium-111 (111In) chelated by the DTPA. The antibody-conjugate specifically binds to GD2, and is useful, for example, in radio-guided and fluorescent-guided surgical techniques for intraoperative detection of GD2-positive cancer tissue.

A logic-gated protein device in which proximity-gated protein trans-splicing governs formation of an active protein from two otherwise inactive fragments.

The present invention relates to multivalent and multispecific nanoparticle platforms and methods. A fusion protein comprising: a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety attached to the first nanocage monomeric subunit; wherein the fusion protein is self-assembled with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

The present invention relates to small molecules having high affinity and specificity to prostrate-specific membrane antigen (PSMA) and methods of using them for therapeutic and diagnostic purposes.

The application belongs to the technical field of material preparation, and relates to a bimodal functional imaging nanomaterial and a preparation method and application thereof. 1‑x Fe x Se2, wherein 0 < x < 1. The preparation method of the bimodal functional imaging nanomaterial comprises the following steps: stirring ferrous sulfate and cysteine in a solvent until uniform, then fully stirring bismuth salt, then adding sodium selenite to perform a heating reaction to obtain a bismuth iron selenium nanocomposite. The bismuth iron selenium nanocomposite provided by the application is uniform in size, regular in morphology, has good water phase dispersibility, and has the performance of simultaneously enhancing MRI imaging and CT imaging.

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

To provide a contrast agent for detecting Programmed Death Ligand 1 (PD-L1), which is expressed on the surface of cells in a subject and the like, with high sensitivity and which is cleared within a short period of time, as well as an imaging method for detecting PD-L1.SOLUTION: An imaging agent has a peptide residue that specifically binds to PD-L1, preferably represented by the following formula (I) [n is 0 or 1; L is a linker; Rpt is a reporting moiety represented by DOTAGA (1,4,7,10-tetraazacyclododecane) coordinated with a 64Cu radioactive metal].SELECTED DRAWING: None

Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.

The present invention provides a multi-arm Anti-CD40 antibody-mediated nanometer dual-drug delivery system and its preparation method and application, belonging to the field of biomedicine technology. In the present invention, chromium ion-doped zinc gallate nanocrystals are embedded in silica-coated gold nanorod nanoparticles GNR@MSNs to prepare composite nanoparticles cGNR@MSNs, and then multi-arm DOTV is modified on the surface of the nanoparticles, and then anti-CD40 antibodies are covalently coupled to obtain the multi-arm Anti-CD40 antibody-mediated nanometer dual-drug delivery system. The multi-arm Anti-CD40 antibody-mediated nanometer dual-drug delivery system improves diagnostic accuracy by combining multimodal imaging, promotes the development of imaging-guided combined therapy, exerts the synergistic effect of chemotherapy, immunotherapy and photothermal therapy, optimizes the tumor treatment effect, is suitable for the treatment of various malignant solid tumors, and has good practicality.

The present invention relates to a compound of the following formula (A) for use mainly as a radiopaque monomer. The present invention further relates to radiopaque embolization microspheres based on at least 20% - 90% hydrophilic monomer, 5% - 50% compound of formula (A), 1% - 15% non - biodegradable hydrophilic cross - linking monomer, and - 0.1% - 10% migrating agent. The present invention also relates to a pharmaceutical composition comprising at least one embolization microsphere according to the invention, preferably with a pharmaceutically acceptable carrier for parenteral administration. The present invention further relates to a kit comprising a pharmaceutical composition according to the invention with a pharmaceutically acceptable carrier for parenteral administration and injection means. TIFF2025521863000019.tif20128

An antibody, or an antigen-binding fragment of same, specifically binding to a BCMA, a nucleic acid encoding same, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof in treating a disease, for example, the use thereof in treating a tumour.

The technology relates to a method for detecting high-risk unstable atherosclerotic plaque in a subject, the method comprising: a) administering to the subject a magnetic resonance imaging (MRI) contrast agent capable of being activated by myeloperoxidase (MPO) in atherosclerotic plaque; b) allowing the contrast agent to be activated by myeloperoxidase in atherosclerotic plaque; c) obtaining an image of the atherosclerotic plaque from the subject using such molecular MRI, wherein enhanced imaging is indicative of unstable plaque. In some embodiments an MPO inhibitor is administered to a subject identified as having a high-risk unstable atherosclerotic plaque.

Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groups.

The invention discloses a manganese phenol network coated polyethyleneimine stabilized polypyrrole nanoparticle and application thereof, and belongs to the technical field of biological medicine. Hyperbranched polyethyleneimine is used as a carrier, polypyrrole and Mn < 2 + > are integrated in a functionalized PEI.NH2 nano system, PPy nanoparticles are stabilized through the functionalized PEI.NH2, then gold nanoparticles are wrapped in the functionalized PEI.NH2, and finally the nano composite system is wrapped with a tannic acid-manganese ion network through a one-step assembly method. The preparation method comprises the following steps: constructing a PEI.NH2 stable PPy nanoparticle Au-PPy PPSNs (at) TMn coated with a manganese phenol network; according to the Au-PPy PPSNs (at) TMn disclosed by the invention, CDT / PTT synergistic treatment and CT / MR (Computed Tomography / Magnetic Resonance) bimodal imaging of cancer cells can be realized.

The invention relates to a breast cancer diagnosis probe, in particular to a fluorescence / magnetic resonance enhanced bimodal breast cancer imaging polypeptide probe as well as a preparation method and application thereof. The polypeptide probe is prepared from a fluorescence imaging unit, a magnetic resonance imaging unit, a self-assembly imaging unit and a TROP-2 targeted recognition unit. According to the invention, the polypeptide probe for enhancing fluorescence / magnetic resonance signals through in-situ self-assembly is constructed, and the polypeptide probe synthesized through modular optimization can realize in-situ self-assembly mediated by high-expression TROP-2 protein of triple negative breast cancer cells; self-assembly along with fluorescence and magnetic resonance unit aggregation can significantly enhance fluorescence and magnetic resonance bimodal imaging signals of triple-negative breast cancer tissues, improve imaging sensitivity and enhance triple-negative breast cancer imaging effects.

The present invention discloses an ultrasound / magnetic resonance dual-mode nanoprobe and its preparation method and application. The preparation method comprises the following steps: S1, preparing iron sulfide nanosheets (FeS) using ammonium ferrous sulfate, trisodium citrate, etc. as raw materials, and resuspending the FeS in ethanol to obtain an FeS ethanol solution; S2, adding perfluorohexane to the FeS anhydrous ethanol solution, and using an ultrasonic crusher under an ice bath to prepare a FeS / PFH suspension; S3, mixing the FeS / PFH suspension with a 1 mg / mL dopamine hydrochloride anhydrous ethanol solution, stirring at room temperature in the dark, and washing with pure water to obtain the final product, FeS / PFH / PDA nanomaterial. The present invention discloses an ultrasound / magnetic resonance dual-mode nanoprobe and its preparation method and application. The synthesis method for preparing the ultrasound / magnetic resonance dual-mode nanoprobe is simple and highly operable; the synthesized product is stable and reproducible, which is beneficial for biomedical research and clinical disease diagnosis.

The present invention discloses a multi-substrate adhesive hydrogel capable of efficiently delivering nucleic acid molecules and its application in tumor treatment. The preparation steps of the hydrogel are as follows: preparing a MXene nanosheet solution by hydrofluoric acid etching; preparing a disulfide solid powder by recrystallization; mixing the disulfide solid powder with the MXene nanosheet solution and stirring at room temperature to obtain solution A; mixing CpG oligonucleotide with solution A and dialyzing to obtain an ONMs nanoparticle solution; grafting sodium alginate and amino-modified ATP aptamer to obtain DNA SA solution; ONMs nanoparticle solution and DNA SA solution was mixed and incubated at room temperature to obtain DNA SA@ONMs solution; DNA The SA@ONMs solution was mixed with acrylamide, and then an ionic crosslinker, a crosslinker, a crosslinking accelerator, and an initiator were added in sequence. The mixture was stirred at room temperature and allowed to stand to solidify into a gel, thereby obtaining a multi-substrate adhesion hydrogel.